Invesco’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $665M | Sell |
4,429,755
-516,714
| -10% | -$56.2M | 0.05% | 273 |
|
|
2026
Q1 | $457M | Sell |
4,946,469
-369,465
| -7% | -$37.1M | 0.04% | 361 |
|
|
2025
Q4 | $543M | Buy |
5,315,934
+386,391
| +8% | +$34.6M | 0.05% | 286 |
|
|
2025
Q3 | $308M | Buy |
4,929,543
+1,371,042
| +39% | +$74.6M | 0.05% | 470 |
|
|
2025
Q2 | $185M | Buy |
3,558,501
+763,834
| +27% | +$34.1M | 0.03% | 663 |
|
|
2025
Q1 | $119M | Buy |
2,794,667
+1,403,670
| +101% | +$60.6M | 0.02% | 756 |
|
|
2024
Q4 | $42.5M | Sell |
1,390,997
-1,511,077
| -52% | -$42.5M | 0.01% | 1120 |
|
|
2024
Q3 | $66.6M | Buy |
2,902,074
+1,694,605
| +140% | +$48M | 0.01% | 929 |
|
|
2024
Q2 | $34.9M | Sell |
1,207,469
-126,801
| -10% | -$2.95M | 0.01% | 1163 |
|
|
2024
Q1 | $27.5M | Buy |
1,334,270
+244,628
| +22% | +$5.24M | 0.01% | 1290 |
|
|
2023
Q4 | $29.5M | Buy |
1,089,642
+19,490
| +2% | +$511K | 0.01% | 1228 |
|
|
2023
Q3 | $31.7M | Buy |
1,070,152
+179,593
| +20% | +$6.32M | 0.01% | 1141 |
|
|
2023
Q2 | $31.9M | Sell |
890,559
-1,262,967
| -59% | -$36.3M | 0.01% | 1126 |
|
|
2023
Q1 | $50.5M | Buy |
2,153,526
+1,283,502
| +148% | +$36.7M | 0.01% | 954 |
|
|
2022
Q4 | $23.7M | Buy |
870,024
+242,217
| +39% | +$11.1M | 0.01% | 1293 |
|
|
2022
Q3 | $33.8M | Buy |
627,807
+475,745
| +313% | +$24.4M | 0.01% | 1055 |
|
|
2022
Q2 | $6.13M | Buy |
152,062
+5,711
| +4% | +$283K | ﹤0.01% | 2167 |
|
|
2022
Q1 | $9.69M | Sell |
146,351
-29,355
| -17% | -$2.01M | ﹤0.01% | 1981 |
|
|
2021
Q4 | $17.6M | Sell |
175,706
-741,369
| -81% | -$76.7M | ﹤0.01% | 1649 |
|
|
2021
Q3 | $115M | Buy |
917,075
+54,549
| +6% | +$6.48M | 0.03% | 753 |
|
|
2021
Q2 | $107M | Sell |
862,526
-64,692
| -7% | -$8.7M | 0.03% | 809 |
|
|
2021
Q1 | $142M | Buy |
927,218
+529,671
| +133% | +$80.1M | 0.04% | 638 |
|
|
2020
Q4 | $51.2M | Buy |
397,547
+238,216
| +150% | +$27.4M | 0.01% | 1014 |
|
|
2020
Q3 | $17.8M | Sell |
159,331
-58,099
| -27% | -$5.31M | 0.01% | 1361 |
|
|
2020
Q2 | $17.6M | Buy |
217,430
+3,585
| +2% | +$289K | 0.01% | 1330 |
|
|
2020
Q1 | $14.9M | Buy |
213,845
+6,565
| +3% | +$504K | 0.01% | 1336 |
|
|
2019
Q4 | $16.2M | Buy |
207,280
+2,111
| +1% | +$152K | 0.01% | 1533 |
|
|
2019
Q3 | $13.1M | Buy |
205,169
+19,396
| +10% | +$1.71M | ﹤0.01% | 1615 |
|
|
2019
Q2 | $16M | Buy |
185,773
+129,343
| +229% | +$9.88M | ﹤0.01% | 1549 |
|
|
2019
Q1 | $4.33M | Buy |
+56,430
| New | +$3.13M | ﹤0.01% | 2098 |
|
Other funds holding GH
DTC
Invesco's GH Position: Q2 2026 in Review
Invesco reduced its Guardant Health (GH) stake by 10% in Q2 2026, selling an estimated $56.2M and leaving 4,429,755 shares worth $665M. The position accounts for 0.05% of the portfolio, ranked #273.
Invesco first reported a position in GH in Q1 2019 and has held it in 30 quarters since. 596 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Invesco held 4,429,755 shares of Guardant Health worth $665M as of Q2 2026.
- Invesco sold 516,714 Guardant Health shares in Q2 2026, an estimated $56.2M.
- Guardant Health made up 0.05% of Invesco's portfolio in Q2 2026, its #273 holding.
- Invesco first reported a position in Guardant Health in Q1 2019 and has held it in 30 quarters since.
- 596 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.